The purpose of the review is to summarize the current pharmacological management of chronic kidney disease (CKD) in pediatric patients and critically present emerging evidence for the use of mineralocorticoid receptor antagonists and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Globally, CKD is the 19th leading cause of years of life lost and the current total number of children and adolescents affected with CKD Stages II-V is predicted to exceed 2 million in a global population of 2 billion children. The severity of kidney disease is strongly correlated with the extent of proteinuria. Agents that target the renin-angiotensin-aldosterone-system reduce proteinuria in mild to moderate CKD, slowing disease progression. Recent clinical trials evaluating mineralocorticoid receptor antagonists, such as finerenone and SGLT2 inhibitors, demonstrate similar results. However, additional pediatric clinical trials are necessary to determine their complete therapeutic potential.
Birincil Dil | İngilizce |
---|---|
Konular | Çocuk Sağlığı ve Hastalıkları (Diğer) |
Bölüm | Derlemeler |
Yazarlar | |
Yayımlanma Tarihi | 20 Şubat 2024 |
Gönderilme Tarihi | 11 Aralık 2023 |
Kabul Tarihi | 14 Aralık 2023 |
Yayımlandığı Sayı | Yıl 2024 |